Pfizer Shares Up 51% Since the Start of the Year. What’s Next?
<p><a href='https://financialmodelingprep.com/financial-summary/PFE'>Pfizer Inc. (NYSE:PFE) </a>shares are up around 51% since the start of the year, as demand for the COVID-19 vaccine – Comirnaty – has continued to build through 2021. As the Omicron variant causes COVID-19 infection rates to rise once again, analysts at Berenberg Bank expect demand for Comirnaty to remain high in 2022 (at least $29 billion in sales). </p>
<p>Following impressive clinical data, the analysts now expect Pfizer to sell all it can manufacture of Paxlovid (the COVID-19 antiviral) next year, contributing a further $27 billion in sales.</p>
<p>A key debate among investors is how sustainable COVID-19-related sales and profits will be. Given vaccine competition and the preferential characteristics of Pfizer’s antiviral (superior clinical data and much higher margin than Comirnaty), analysts expect Paxlovid to rapidly become the larger profit driver. </p>
<p>Berenberg Bank’s base-case assumptions assume COVID-19 franchise peak sales of almost $60 billion in 2022, before falling back to $2-4 billion in sales per year from 2025 onwards.</p>

NYSE:PFE